HLA-ABC Antikörper
Kurzübersicht für HLA-ABC Antikörper (ABIN3023755)
Target
Alle HLA-ABC Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Produktmerkmale
- Reacts with a monomorphic determinant of human major histocompatibility (MHC) class I antigens (HLA-A, B and C). Human MHC class I antigens are expressed constitutively on all nucleated cells lymphocytes such as lymphocytes, thymocytes, granulocytes, and bone marrow cells and are absent on erythrocytes. MHC class I antigens play a role in class I MHC-associated antigen presentation, inhibition of NK cell cytotoxicity, tumor surveillance, and tissue allotransplantation.
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- Human peripheral blood leukocytes were used as the immunogen for the HLA-ABC antibody.
-
Isotyp
- IgG2a kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the HLA-ABC antibody should be determined by the researcher.\. Western blot: 1-2 μg/mL, Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Konservierungsmittel
- Azide free
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the HLA-ABC antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- HLA-ABC
-
Andere Bezeichnung
- HLA-ABC (MHC I)
-
Hintergrund
- Reacts with a monomorphic determinant of human major histocompatibility (MHC) class I antigens (HLA-A, B and C). Human MHC class I antigens are expressed constitutively on all nucleated cells lymphocytes such as lymphocytes, thymocytes, granulocytes, and bone marrow cells and are absent on erythrocytes. MHC class I antigens play a role in class I MHC-associated antigen presentation, inhibition of NK cell cytotoxicity, tumor surveillance, and tissue allotransplantation.
-
Pathways
- T-Zell Rezeptor Signalweg, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-